A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of...
Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech...
Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposureCompany continues activities necessary to advance its Sildenafil Cream toward the...
This is the newest page. Registered accounts read further back.